Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $547.49, for a total value of $5,201,155.00. Following the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $22,180,462.37. This trade represents a 19.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

United Therapeutics Stock Up 1.6%

Shares of UTHR traded up $8.45 during mid-day trading on Tuesday, hitting $553.14. The stock had a trading volume of 325,572 shares, compared to its average volume of 479,193. The company has a market cap of $23.48 billion, a PE ratio of 20.42, a PEG ratio of 1.79 and a beta of 0.57. The company’s fifty day simple moving average is $568.47 and its two-hundred day simple moving average is $519.64. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics’s revenue was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $6.63 EPS. Equities analysts expect that United Therapeutics Corporation will post 26.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Oppenheimer boosted their price objective on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. HC Wainwright boosted their price objective on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Cantor Fitzgerald boosted their price objective on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. Finally, Raymond James Financial assumed coverage on United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective for the company. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $619.42.

Institutional Trading of United Therapeutics

Several hedge funds have recently added to or reduced their stakes in UTHR. Torren Management LLC bought a new stake in United Therapeutics during the 4th quarter valued at $26,000. Activest Wealth Management raised its stake in United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares in the last quarter. WealthCollab LLC raised its stake in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. raised its stake in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares in the last quarter. Finally, Entrust Financial LLC bought a new stake in United Therapeutics during the 4th quarter valued at $31,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.